Epogen / Procrit (epoetin alfa) — HCPCS J0885

Dual-brand: Epogen + Procrit = same molecule FDA verified May 2026

Two brand names, one HCPCS code. Co-licensed since the late 1980s.

Epogen (Amgen) and Procrit (Janssen Biotech) are the same biologic — recombinant human erythropoietin (epoetin alfa, BLA 103234). Amgen developed and licensed the molecule, retained the Epogen trade name (historically marketed for dialysis CKD anemia), and granted Janssen rights to market the same product as Procrit (historically for non-ESRD indications). Both are commercially available under both names today, sourced from the same Amgen manufacturing process.

J0885 (non-ESRD) vs Q4081 (ESRD on dialysis) CMS verified May 2026

Same drug, two HCPCS codes — the trigger is whether the patient is on chronic dialysis for ESRD.

Dosing & unit math FDA label verified May 2026

From FDA prescribing information, BLA 103234.

CKD anemia (non-dialysis adults)

• Initiate: 50–100 IU/kg SC 3× weekly
• Target: Hgb 10–11 g/dL (do not exceed 11 g/dL per CMS NCD 110.21 / payer policy)
• Iron status required: TSAT ≥20%, ferritin ≥100 ng/mL before initiation
• Dose adjustment: hold/reduce by 25% if Hgb rises >1 g/dL in 2 weeks; increase by 25% if Hgb has not risen by >1 g/dL after 4 weeks (but only if Hgb <10)

CKD anemia (hemodialysis adults — bills under Q4081)

• Initial 50 IU/kg IV 3× weekly during dialysis
• Target Hgb 10–11 g/dL; bundled into ESRD PPS

Chemotherapy-induced anemia (CIA, non-myeloid malignancies)

• Standard: 150 IU/kg SC 3× weekly OR 40,000 IU SC weekly
• If no Hgb response after 4 weeks at 40,000 IU: titrate to 60,000 IU SC weekly
• Discontinue if no response (Hgb increase <1 g/dL from baseline) after 8 weeks total
• Discontinue when chemotherapy course completes (do not continue post-chemo)
• ESA APPRISE Oncology REMS REQUIRED — see REMS section

Perioperative anemia (autologous transfusion reduction)

• 600 IU/kg SC weekly × 3 doses pre-op (21, 14, and 7 days before surgery) + 1 dose day-of-surgery
• Limited to elective, non-cardiac, non-vascular surgery
• DVT prophylaxis recommended (Boxed Warning, thrombosis risk)

HIV / zidovudine-induced anemia

• 100 IU/kg SC or IV 3× weekly × 8 weeks; titrate based on response
• Maintenance dosing variable; target Hgb ≤12 g/dL (older label, predates 2011 target revision)

Worked example — 70 kg patient on chemo (40,000 IU SC weekly)

No premedication routinely required, but iron is

ESAs do not require pre-medication. They DO require iron repletion: most payers require documented TSAT ≥20% and ferritin ≥100 ng/mL before ESA initiation, and ongoing iron supplementation (oral or IV iron such as Venofer J1756, Injectafer J1439, or Monoferric J1437) during therapy. ESA without iron is a common denial.

ESA class comparison — J0885 vs alternatives CMS HCPCS verified May 2026

Four ESA products in the U.S. market. Same therapeutic class, different molecules, different dosing intervals, different costs.

NDC reference FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Epoetin alfa is supportive care, NOT chemotherapy — use therapeutic admin codes, not chemo admin codes.

Modifiers CMS verified May 2026

JZ — required on every non-ESRD SDV claim with no waste

Effective July 1, 2023, CMS requires JZ on all single-dose container claims when no drug is discarded. For Epogen / Procrit, JZ applies when the dose matches the vial size exactly (e.g., 10,000 IU dose using one 10,000 IU SDV; 40,000 IU using one 40,000 IU SDV). One of JZ or JW must be on every J0885 SDV claim.

JW — report discarded portion of SDV

JW reports the discarded portion when the dose is smaller than the vial. Example: a 70 kg patient receiving 7,000 IU (100 IU/kg) from a 10,000 IU SDV discards 3,000 IU. Bill 7 units of J0885 with JZ-style admin documentation, plus a JW line for the 3 units discarded. The wasted 3 units are reimbursable but must be reported.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the injection. Routine ESA monitoring labs (CBC) and brief symptom check are bundled into the injection.

340B modifiers (JG, TB)

For 340B-acquired Epogen / Procrit, follow your MAC's current 340B modifier policy. ESAs are commonly 340B-acquired in covered hospital outpatient and oncology clinic settings.

ICD-10-CM by indication FY2026 verified May 2026

ESA medical necessity requires anemia diagnosis (D64.81 or condition-specific) PLUS an underlying-cause code.

Site of care & place of service Verified May 2026

ESA site-of-care UM is less aggressive than for high-cost monoclonal antibodies, but commercial payers increasingly steer ESAs out of HOPD for chronic dosing.

ESRD PPS bundling CMS ESRD PPS Final Rule

For in-center HD patients, epoetin alfa is bundled into the per-treatment ESRD payment — do not bill J0885 or Q4081 separately.

Since January 1, 2011, the Medicare ESRD Prospective Payment System (PPS) bundles all ESRD-related services, including ESAs, IV iron, vitamin D analogs, and dialysis-related labs, into a single per-treatment payment to the dialysis facility. Q4081 is reported on the dialysis claim (UB-04, 837I, revenue code 0634 or 0635) for ESA-APPRISE tracking and audit purposes — but it is not separately payable.

Claim form field mapping Verified May 2026

From Amgen / Janssen access program guides + CMS Medicare Claims Processing Manual Ch. 17.

Payer policy snapshot + Hgb 10–11 g/dL target Reviewed May 2026

All major payers cap continued ESA dosing at Hgb >11 g/dL and require iron-replete state.

Hgb monitoring + dose hold rules

• Hgb >11 g/dL: hold dose; resume at 25% lower when Hgb <10
• Hgb rises >1 g/dL in 2 weeks: reduce dose by 25%
• No response (Hgb rise <1 g/dL) after 8 weeks at appropriate dose: discontinue (CIA)
• Iron status quarterly: TSAT ≥20%, ferritin ≥100 ng/mL maintenance; lower targets fail to maintain Hgb

Step therapy

Generally not required for the labeled CKD anemia and CIA indications. Some payers require biosimilar Retacrit (Q5106) before originator J0885 for non-ESRD indications — verify formulary position. Aranesp (J0881) and Mircera (J0888) are usually parity options; some plans prefer one.

ESA APPRISE Oncology REMS FDA REMS verified May 2026

Required for chemotherapy-induced anemia (cancer) use. Joint REMS held by Amgen and Janssen.

The ESA APPRISE (Assisting Providers and cancer Patients with Risk Information for the Safe use of ESAs) Oncology Program is the FDA-mandated REMS for use of erythropoiesis-stimulating agents in patients with cancer receiving chemotherapy. It applies to Epogen, Procrit, Aranesp, and biosimilars (Retacrit). It does NOT apply to CKD anemia, perioperative anemia, or HIV anemia.

What's required

• Prescriber enrollment in ESA APPRISE before prescribing for cancer indication
• Patient Acknowledgment Form — signed before each chemotherapy course (not each dose)
• Provider Acknowledgment Form — co-signed at the same encounter
• Annual prescriber renewal (re-confirm enrollment)
• Forms maintained in patient chart for audit (commercial + CMS audits both common)

Enrollment

• Web: esa-apprise.com
• Phone: 1-866-284-8089
• Joint REMS held by Amgen Inc. and Janssen Biotech, Inc.; covers Epogen, Procrit, Aranesp, biosimilars

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

NCD 110.21 — Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions: established coverage criteria for chemo-induced anemia (Hgb <10 at initiation, discontinue if no response after 8 weeks, off chemo course = stop). Local coverage policies (LCDs) elaborate on CKD non-dialysis dosing limits.

Code history

• J0885 — permanent code, "Injection, epoetin alfa, (for non-ESRD use), 1,000 units" — long-standing since the late 1990s
• Q4081 — permanent code for ESRD-on-dialysis use, bundled into ESRD PPS effective January 1, 2011
• Q5105 — Retacrit (epoetin alfa-epbx, biosimilar) ESRD use; effective April 1, 2019
• Q5106 — Retacrit non-ESRD use; effective April 1, 2019

Patient assistance — Amgen Assist 360 + Janssen CarePath Verified May 2026

Epogen — Amgen Assist 360

• Phone: 1-888-427-7478
• Web: amgenassist360.com
• Benefits investigation, prior authorization assistance, appeals support
• Commercial copay program (eligibility excludes Medicare, Medicaid, federal program patients)
• Amgen Safety Net Foundation (Amgen SNF) — free product for uninsured / underinsured

Procrit — Janssen CarePath

• Phone: 1-877-CarePath (1-877-227-3728)
• Web: janssencarepath.com
• Benefits investigation, PA assistance, denial / appeal support
• Commercial copay program (similar federal-program exclusions)
• Johnson & Johnson Patient Assistance Foundation — free product for income-qualified uninsured

Independent foundations (for Medicare patients)

• HealthWell Foundation, PAN Foundation, CancerCare — verify open ESA / CKD anemia / CIA funds quarterly
• National Kidney Foundation — CKD-specific copay support intermittently

Boxed Warning FDA Black Box 2007

Mortality, cardiovascular events, thromboembolism, stroke, and tumor progression. The reason for the 10–11 g/dL Hgb cap.

What this means for billing

• Hgb >11 g/dL = stop dosing (and almost always = denial of next claim)
• Cancer use without ESA APPRISE forms = audit risk + recoupment
• Iron repletion is mandatory; ESA without iron supplementation is non-standard care and may deny
• For perioperative use, document DVT prophylaxis plan

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Epogen and Procrit?

Both Epogen (Amgen) and Procrit (Janssen Biotech) bill under HCPCS J0885 — "Injection, epoetin alfa, (for non-ESRD use), 1,000 units." Same molecule, two brand names, one billing code. The unit basis is unusual: 1 billing unit = 1,000 IU. ESRD-on-dialysis use is billed under Q4081 instead, which is bundled into the ESRD PPS payment.

How many units do I bill for a 10,000 IU dose?

Bill 10 units of J0885 for a 10,000 IU dose. The unit conversion is the most common error on this code: 1 J0885 unit = 1,000 IU, so divide IU by 1,000 to get billing units. 4,000 IU = 4 units; 10,000 IU = 10 units; 40,000 IU = 40 units; 60,000 IU = 60 units.

What's the difference between J0885 and Q4081?

J0885 is for non-ESRD use of epoetin alfa (CKD not on dialysis, chemo-induced anemia, perioperative anemia, HIV anemia from zidovudine), with unit basis 1,000 IU per unit, separately payable Part B drug at ASP+6%. Q4081 is for ESRD-on-dialysis use, with unit basis 100 IU per unit, bundled into the ESRD PPS per-treatment payment (not separately payable). The trigger is Z99.2 (chronic dialysis dependence) on the claim.

What admin code do I use for Epogen?

For SC administration (most common for non-dialysis CKD, chemo-induced anemia, perioperative): CPT 96372 (therapeutic SC injection). For IV in non-ESRD outpatient settings: 96365 (therapeutic IV infusion) or 96374 (IV push). For HD patients during dialysis, the admin is bundled into the ESRD PPS — no separate admin code billable. Do NOT use chemo admin codes (96401–96425).

What is the Medicare reimbursement for J0885?

For Q2 2026, the Medicare Part B payment limit for J0885 is $7.305 per 1,000 IU unit (ASP + 6%). A 10,000 IU dose reimburses at approximately $73.05 (10 units × ASP+6%). A 40,000 IU weekly dose for chemo-induced anemia reimburses at approximately $292.20. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.

Is ESA APPRISE REMS required?

Yes — but only for the cancer (chemotherapy-induced anemia) indication. The ESA APPRISE Oncology Program is a joint REMS held by Amgen and Janssen requiring prescriber enrollment and Patient/Provider Acknowledgment Forms before each chemo course. ESA APPRISE is NOT required for CKD anemia, perioperative anemia, or HIV-related anemia.

What is the target hemoglobin for ESA therapy?

Per CMS NCD 110.21 and most major commercial payer policies, target Hgb is 10–11 g/dL. Continued ESA dosing at Hgb >11 will be denied. Required: Hgb <10 at initiation, iron-replete state (TSAT ≥20%, ferritin ≥100 ng/mL), hold/reduce if Hgb rises >1 g/dL in 2 weeks, discontinue chemo-induced anemia treatment if no response after 8 weeks.

What does the Boxed Warning say?

ESAs (epoetin alfa included) carry an FDA Boxed Warning added in 2007 describing increased risk of death, serious cardiovascular events, thromboembolism, and stroke when administered to target Hgb >11 g/dL; tumor progression and shortened overall survival in cancer patients outside the ESA APPRISE-approved labeling; and recommended DVT prophylaxis for perioperative use due to thrombosis risk. Use the lowest dose to avoid transfusion.

How does Retacrit (biosimilar) compare?

Retacrit (Q5105 / Q5106, epoetin alfa-epbx) is the FDA-approved biosimilar of Procrit/Epogen, approved May 2018, manufactured by Pfizer (Hospira/Vifor). Same molecule (matched by biosimilar designation), typically priced 20–40% below originator ASP. Many large oncology and dialysis purchasing organizations have moved to Retacrit as preferred. Some commercial payers require Retacrit step before originator J0885.

Source documents

1. DailyMed — EPOGEN / PROCRIT (epoetin alfa) Prescribing Information
   FDA-approved label, BLA 103234. Boxed Warning added 2007.
2. Amgen Assist 360 — Epogen patient and provider support
   Phone: 1-888-427-7478
3. Janssen CarePath — Procrit patient and provider support
   Phone: 1-877-227-3728 (1-877-CarePath)
4. ESA APPRISE Oncology Program — joint REMS (Amgen + Janssen)
   Required for cancer (chemo-induced anemia) use. Phone: 1-866-284-8089.
5. CMS NCD 110.21 — Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions
6. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
7. CMS — ESRD Prospective Payment System
   Bundled payment for in-center HD covers Q4081 ESA dosing
8. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease
9. SEER CanMED — HCPCS J0885 reference
10. UnitedHealthcare — Erythropoiesis Stimulating Agents Medical Drug Policy
11. Aetna CPB 0195 — Erythropoiesis Stimulating Agents
12. FDA National Drug Code Directory

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. ASP data: Q2 2026 ($7.305/unit). Sources: FDA label (most recent rev incl. 2007 Boxed Warning), CMS NCD 110.21, CMS ESRD PPS, KDIGO CKD anemia guidelines, Amgen Assist 360, Janssen CarePath, ESA APPRISE Oncology REMS, UHC + Aetna ESA policies. Dual-brand (Epogen + Procrit) treatment, J0885 vs Q4081 distinction, ESA class comparison (Aranesp / Mircera / Retacrit biosimilar) all included.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. ESA APPRISE program details are read directly from the joint Amgen / Janssen REMS website. We do not paraphrase from billing-software vendor blogs.